{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T05:58:33Z","timestamp":1776751113950,"version":"3.51.2"},"reference-count":149,"publisher":"Elsevier","isbn-type":[{"value":"9780323988513","type":"print"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/bs.acc.2022.03.002","type":"book-chapter","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T08:13:21Z","timestamp":1650874401000},"page":"31-73","source":"Crossref","is-referenced-by-count":13,"title":["Biomarkers in cardiogenic shock"],"prefix":"10.1016","member":"78","reference":[{"issue":"8","key":"10.1016\/bs.acc.2022.03.002_bb0010","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/ejhf.1922","article-title":"Epidemiology, pathophysiology and contemporary management of cardiogenic shock - a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"22","author":"Chioncel","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/bs.acc.2022.03.002_bb0015","author":"Ponikowski","year":"2016","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/bs.acc.2022.03.002_bb0020","first-page":"29","volume":"94","author":"Baran","year":"2019","journal-title":"Catheter. Cardiovasc. Interv."},{"issue":"14","key":"10.1016\/bs.acc.2022.03.002_bb0025","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1208410","article-title":"Intraaortic balloon support for myocardial infarction with cardiogenic shock","volume":"367","author":"Thiele","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2022.03.002_bb0030","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1710261","article-title":"PCI strategies in patients with acute myocardial infarction and cardiogenic shock","author":"Thiele","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/bs.acc.2022.03.002_bb0035","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1161\/CIR.0000000000000525","article-title":"Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association","volume":"136","author":"van Diepen","year":"2017","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/bs.acc.2022.03.002_bb0040","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S2213-8587(13)70154-2","article-title":"Stress hyperlactataemia: present understanding and controversy","volume":"2","author":"Garcia-Alvarez","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"24","key":"10.1016\/bs.acc.2022.03.002_bb0045","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1056\/NEJMra1309483","article-title":"Lactic acidosis","volume":"371","author":"Kraut","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/bs.acc.2022.03.002_bb0050","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/SHK.0b013e318167378f","article-title":"Increased aerobic glycolysis through beta2 stimulation is a common mechanism involved in lactate formation during shock states","volume":"30","author":"Levy","year":"2008","journal-title":"Shock"},{"issue":"10","key":"10.1016\/bs.acc.2022.03.002_bb0055","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1097\/01.CCM.0000181525.99295.8F","article-title":"Lactate and glucose metabolism in severe sepsis and cardiogenic shock","volume":"33","author":"Revelly","year":"2005","journal-title":"Crit. Care Med."},{"issue":"12","key":"10.1016\/bs.acc.2022.03.002_bb0060","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1097\/00003246-200012000-00002","article-title":"Effects of cardiogenic shock on lactate and glucose metabolism after heart surgery","volume":"28","author":"Chiolero","year":"2000","journal-title":"Crit. Care Med."},{"issue":"8","key":"10.1016\/bs.acc.2022.03.002_bb0065","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.011991","article-title":"Cardiogenic shock","volume":"8","author":"Vahdatpour","year":"2019","journal-title":"J. Am. Heart Assoc."},{"issue":"5","key":"10.1016\/bs.acc.2022.03.002_bb0070","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/ejhf.260","article-title":"Clinical picture and risk prediction of short-term mortality in cardiogenic shock","volume":"17","author":"Harjola","year":"2015","journal-title":"Eur. J. Heart Fail."},{"issue":"1","key":"10.1016\/bs.acc.2022.03.002_bb0075","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s13054-016-1387-1","article-title":"Current real-life use of vasopressors and inotropes in cardiogenic shock\u2014adrenaline use is associated with excess organ injury and mortality","volume":"20","author":"Tarvasmaki","year":"2016","journal-title":"Crit. Care"},{"issue":"3","key":"10.1016\/bs.acc.2022.03.002_bb0080","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s00134-016-4223-9","article-title":"The ENCOURAGE mortality risk score and analysis of long-term outcomes after VA-ECMO for acute myocardial infarction with cardiogenic shock","volume":"42","author":"Muller","year":"2016","journal-title":"Intensive Care Med."},{"key":"10.1016\/bs.acc.2022.03.002_bb0085","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jcrc.2017.06.022","article-title":"Lactate and lactate clearance as valuable tool to evaluate ECMO therapy in cardiogenic shock","volume":"42","author":"Slottosch","year":"2017","journal-title":"J. Crit. Care"},{"issue":"2","key":"10.1016\/bs.acc.2022.03.002_bb0090","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/ehf2.13200","article-title":"Impella versus extracorporal life support in cardiogenic shock: a propensity score adjusted analysis","volume":"8","author":"Wernly","year":"2021","journal-title":"ESC Heart Fail."},{"issue":"3","key":"10.1016\/bs.acc.2022.03.002_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229135","article-title":"Lactate indices as predictors of in-hospital mortality or 90-day survival after admission to an intensive care unit in unselected critically ill patients","volume":"15","author":"Hayashi","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2022.03.002_bb0100","article-title":"Use of noninvasive and invasive mechanical ventilation in cardiogenic shock: a prospective multicenter study","author":"Hongisto","year":"2016","journal-title":"Int. J. Cardiol."},{"issue":"1","key":"10.1016\/bs.acc.2022.03.002_bb0105","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/SHK.0000000000001353","article-title":"Serum lactate and A relative change in lactate as predictors of mortality in patients with cardiogenic shock\u2014results from the Cardshock Study","volume":"53","author":"Lindholm","year":"2020","journal-title":"Shock"},{"issue":"3","key":"10.1016\/bs.acc.2022.03.002_bb0110","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/ejhf.958","article-title":"Acute kidney injury in cardiogenic shock: definitions, incidence, haemodynamic alterations, and mortality","volume":"20","author":"Tarvasmaki","year":"2018","journal-title":"Eur. J. Heart Fail."},{"issue":"1","key":"10.1016\/bs.acc.2022.03.002_bb0115","first-page":"38","article-title":"Altered mental status predicts mortality in cardiogenic shock\u2014results from the CardShock study","volume":"7","author":"Kataja","year":"2018","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"issue":"7","key":"10.1016\/bs.acc.2022.03.002_bb0120","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.amjcard.2017.06.049","article-title":"Frequency and prognostic significance of abnormal liver function tests in patients with cardiogenic shock","volume":"120","author":"Jantti","year":"2017","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/bs.acc.2022.03.002_bb0125","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ijcard.2020.08.069","article-title":"Kinetics of procalcitonin, C-reactive protein and interleukin-6 in cardiogenic shock\u2014insights from the CardShock study","volume":"322","author":"Kataja","year":"2021","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/bs.acc.2022.03.002_bb0130","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ijcard.2016.10.033","article-title":"The association of admission blood glucose level with the clinical picture and prognosis in cardiogenic shock\u2014results from the CardShock Study","volume":"226","author":"Kataja","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/bs.acc.2022.03.002_bb0135","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1757-7241-19-74","article-title":"Blood lactate as a predictor for in-hospital mortality in patients admitted acutely to hospital: a systematic review","volume":"19","author":"Kruse","year":"2011","journal-title":"Scand. J. Trauma Resusc. Emerg. Med."},{"issue":"2","key":"10.1016\/bs.acc.2022.03.002_bb0140","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s00134-015-4127-0","article-title":"Severe hyperlactatemia, lactate clearance and mortality in unselected critically ill patients","volume":"42","author":"Haas","year":"2016","journal-title":"Intensive Care Med."},{"issue":"1","key":"10.1016\/bs.acc.2022.03.002_bb0145","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s13054-016-1403-5","article-title":"The value of blood lactate kinetics in critically ill patients: a systematic review","volume":"20","author":"Vincent","year":"2016","journal-title":"Crit. Care"},{"issue":"15","key":"10.1016\/bs.acc.2022.03.002_bb0150","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.jacc.2017.02.027","article-title":"Risk stratification for patients in cardiogenic shock after acute myocardial infarction","volume":"69","author":"Poss","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/bs.acc.2022.03.002_bb0155","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehab110","article-title":"The novel cystatin C, lactate, interleukin-6, and N-terminal pro-B-type natriuretic peptide (CLIP)-based mortality risk score in cardiogenic shock after acute myocardial infarction","author":"Ceglarek","year":"2021","journal-title":"Eur. Heart J."},{"issue":"19","key":"10.1016\/bs.acc.2022.03.002_bb0160","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1016\/j.jcin.2020.06.037","article-title":"Arterial lactate in cardiogenic shock: prognostic value of clearance versus single values","volume":"13","author":"Fuernau","year":"2020","journal-title":"JACC Cardiovasc. Interv."},{"issue":"33","key":"10.1016\/bs.acc.2022.03.002_bb0165","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1093\/eurheartj\/ehv194","article-title":"Predicting survival after ECMO for refractory cardiogenic shock: the survival after veno-arterial-ECMO (SAVE)-score","volume":"36","author":"Schmidt","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/bs.acc.2022.03.002_bb0170","article-title":"Predicting mortality in cardiogenic shock secondary to ACS requiring short-term mechanical circulatory support: the ACS-MCS score","author":"Marashly","year":"2021","journal-title":"Catheter. Cardiovasc. Interv."},{"issue":"1","key":"10.1016\/bs.acc.2022.03.002_bb0175","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1373\/clinchem.2008.106500","article-title":"Clinical performance of two highly sensitive cardiac troponin I assays","volume":"55","author":"Venge","year":"2009","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2022.03.002_bb0180","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehy655","article-title":"Fourth universal definition of myocardial infarction (2018)","author":"Thygesen","year":"2018","journal-title":"Eur. Heart J."},{"issue":"9","key":"10.1016\/bs.acc.2022.03.002_bb0185","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJM199908263410901","article-title":"Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock","volume":"341","author":"Hochman","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/bs.acc.2022.03.002_bb0190","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1056\/NEJMoa0907118","article-title":"Comparison of dopamine and norepinephrine in the treatment of shock","volume":"362","author":"De Backer","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/bs.acc.2022.03.002_bb0195","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1093\/eurheartj\/ehs191","article-title":"Troponin elevation in patients with heart failure: on behalf of the third universal definition of myocardial infarction global task force: heart failure section","volume":"33","author":"Januzzi","year":"2012","journal-title":"Eur. Heart J."},{"issue":"7","key":"10.1016\/bs.acc.2022.03.002_bb0200","doi-asserted-by":"crossref","first-page":"e666","DOI":"10.1097\/CCM.0000000000002336","article-title":"Combined measurement of soluble ST2 and amino-terminal pro-B-type natriuretic peptide provides early assessment of severity in cardiogenic shock complicating acute coronary syndrome","volume":"45","author":"Tolppanen","year":"2017","journal-title":"Crit. Care Med."},{"issue":"7","key":"10.1016\/bs.acc.2022.03.002_bb0205","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/eurheartj\/eht466","article-title":"Natriuretic peptides in cardiovascular diseases: current use and perspectives","volume":"35","author":"Volpe","year":"2014","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/bs.acc.2022.03.002_bb0210","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJMoa020233","article-title":"Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure","volume":"347","author":"Maisel","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/bs.acc.2022.03.002_bb0215","doi-asserted-by":"crossref","first-page":"R37","DOI":"10.1186\/cc4839","article-title":"Natriuretic peptide testing for the evaluation of critically ill patients with shock in the intensive care unit: a prospective cohort study","volume":"10","author":"Januzzi","year":"2006","journal-title":"Crit. Care"},{"issue":"7","key":"10.1016\/bs.acc.2022.03.002_bb0220","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1056\/NEJMoa031681","article-title":"Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea","volume":"350","author":"Mueller","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/bs.acc.2022.03.002_bb0225","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ahj.2009.11.001","volume":"159","author":"Jarai","year":"2010","journal-title":"Am. Heart J."},{"issue":"1","key":"10.1016\/bs.acc.2022.03.002_bb0230","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1253\/circj.69.83","article-title":"Predictors of mortality in patients with acute myocardial infarction and cardiogenic shock","volume":"69","author":"Katayama","year":"2005","journal-title":"Circ. J."},{"issue":"23","key":"10.1016\/bs.acc.2022.03.002_bb0235","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMra054415","article-title":"Assessing kidney function--measured and estimated glomerular filtration rate","volume":"354","author":"Stevens","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2022.03.002_bb0240","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejim.2019.10.025","article-title":"Creatinine: from physiology to clinical application","volume":"72","author":"Kashani","year":"2020","journal-title":"Eur. J. Intern. Med."},{"issue":"1","key":"10.1016\/bs.acc.2022.03.002_bb0245","first-page":"1","article-title":"Kidney disease: improving global outcomes (KDIGO) acute kidney injury working group KDIGO clinical practice guideline for acute kidney injury","volume":"2","author":"KDIGO","year":"2012","journal-title":"Kidney Int. Suppl."},{"issue":"4","key":"10.1016\/bs.acc.2022.03.002_bb0250","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1161\/CIRCULATIONAHA.117.032722","article-title":"Mild hypothermia in cardiogenic shock complicating myocardial infarction","volume":"139","author":"Fuernau","year":"2019","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/bs.acc.2022.03.002_bb0255","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0002-9343(01)01070-1","article-title":"Prognosis of patients who develop acute renal failure during the first 24 hours of cardiogenic shock after myocardial infarction","volume":"112","author":"Koreny","year":"2002","journal-title":"Am. J. Med."},{"issue":"2","key":"10.1016\/bs.acc.2022.03.002_bb0260","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/CCM.0b013e3181b9eb3b","article-title":"Acute kidney injury in ST-segment elevation acute myocardial infarction complicated by cardiogenic shock at admission","volume":"38","author":"Marenzi","year":"2010","journal-title":"Crit. Care Med."},{"key":"10.1016\/bs.acc.2022.03.002_bb0265","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ijcard.2015.04.242","article-title":"Prognostic impact of established and novel renal function biomarkers in myocardial infarction with cardiogenic shock: a biomarker substudy of the IABP-SHOCK II-trial","volume":"191","author":"Fuernau","year":"2015","journal-title":"Int. J. Cardiol."},{"issue":"3","key":"10.1016\/bs.acc.2022.03.002_bb0270","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.jtcvs.2017.04.042","article-title":"Importance of stratifying acute kidney injury in cardiogenic shock resuscitated with mechanical circulatory support therapy","volume":"154","author":"Abadeer","year":"2017","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/bs.acc.2022.03.002_bb0275","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jcrc.2018.11.004","article-title":"Risk indicators for acute kidney injury in cardiogenic shock","volume":"50","author":"van den Akker","year":"2019","journal-title":"J. Crit. Care"},{"issue":"5","key":"10.1016\/bs.acc.2022.03.002_bb0280","first-page":"462","article-title":"Prognostic implications of fluid balance in ST elevation myocardial infarction complicated by cardiogenic shock","volume":"6","author":"Arbel","year":"2017","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"issue":"1","key":"10.1016\/bs.acc.2022.03.002_bb0285","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/bs.acc.2022.03.002_bb0290","doi-asserted-by":"crossref","first-page":"64","DOI":"10.5414\/CN107324","article-title":"Cystatin C and acute changes in glomerular filtration rate","volume":"78","author":"Odutayo","year":"2012","journal-title":"Clin. Nephrol."},{"issue":"3","key":"10.1016\/bs.acc.2022.03.002_bb0295","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1053\/j.ajkd.2011.02.389","article-title":"Cystatin C in prediction of acute kidney injury: a systemic review and meta-analysis","volume":"58","author":"Zhang","year":"2011","journal-title":"Am. J. Kidney Dis."},{"issue":"1","key":"10.1016\/bs.acc.2022.03.002_bb0300","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11255-015-1150-6","article-title":"A comparison of RIFLE, AKIN, KDIGO, and Cys-C criteria for the definition of acute kidney injury in critically ill patients","volume":"48","author":"Zhou","year":"2016","journal-title":"Int. Urol. Nephrol."},{"issue":"22","key":"10.1016\/bs.acc.2022.03.002_bb0305","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1093\/eurheartj\/ehq293","article-title":"Markers of renal function and acute kidney injury in acute heart failure: definitions and impact on outcomes of the cardiorenal syndrome","volume":"31","author":"Lassus","year":"2010","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/bs.acc.2022.03.002_bb0310","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jacc.2012.11.005","article-title":"Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes","volume":"61","author":"Metra","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/bs.acc.2022.03.002_bb0315","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1046\/j.1444-2892.2003.00240.x","article-title":"Endogenous cardiac opioids: enkephalins in adaptation and protection of the heart","volume":"12","author":"van den Brink","year":"2003","journal-title":"Heart Lung Circ."},{"issue":"12","key":"10.1016\/bs.acc.2022.03.002_bb0320","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1159\/000509352","article-title":"Proenkephalin: a new biomarker for glomerular filtration rate and acute kidney injury","volume":"144","author":"Khorashadi","year":"2020","journal-title":"Nephron"},{"issue":"1","key":"10.1016\/bs.acc.2022.03.002_bb0325","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13613-021-00814-8","article-title":"Predictive value of plasma proenkephalin and neutrophil gelatinase-associated lipocalin in acute kidney injury and mortality in cardiogenic shock","volume":"11","author":"Jantti","year":"2021","journal-title":"Ann. Intensive Care"},{"issue":"6","key":"10.1016\/bs.acc.2022.03.002_bb0330","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1164\/rccm.201910-1950OC","article-title":"Incidence and outcome of subclinical acute kidney injury using penKid in critically ill patients","volume":"202","author":"Depret","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"9","key":"10.1016\/bs.acc.2022.03.002_bb0335","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1042\/CS20171592","article-title":"More than a simple biomarker: the role of NGAL in cardiovascular and renal diseases","volume":"132","author":"Buonafine","year":"2018","journal-title":"Clin. Sci. (Lond.)"},{"issue":"1","key":"10.1016\/bs.acc.2022.03.002_bb0340","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ccc.2019.08.010","article-title":"The role of biomarkers in acute kidney injury","volume":"36","author":"Srisawat","year":"2020","journal-title":"Crit. Care Clin."},{"issue":"1","key":"10.1016\/bs.acc.2022.03.002_bb0345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3343\/alm.2021.41.1.1","article-title":"Biomarker-guided risk assessment for acute kidney injury: time for clinical implementation?","volume":"41","author":"Albert","year":"2021","journal-title":"Ann. Lab. Med."},{"issue":"10","key":"10.1016\/bs.acc.2022.03.002_bb0350","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1097\/01.ASN.0000088027.54400.C6","article-title":"Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury","volume":"14","author":"Mishra","year":"2003","journal-title":"J. Am. Soc. Nephrol."},{"issue":"8","key":"10.1016\/bs.acc.2022.03.002_bb0355","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1515\/cclm-2016-0973","article-title":"Biomarkers of acute kidney injury: the pathway from discovery to clinical adoption","volume":"55","author":"Kashani","year":"2017","journal-title":"Clin. Chem. Lab. Med."},{"issue":"7","key":"10.1016\/bs.acc.2022.03.002_bb0360","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/ejhf.872","article-title":"Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"19","author":"Harjola","year":"2017","journal-title":"Eur. J. Heart Fail."},{"issue":"4","key":"10.1016\/bs.acc.2022.03.002_bb0365","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1097\/01.CCM.0000259462.97164.A0","article-title":"Incidence and prognosis of early hepatic dysfunction in critically ill patients--a prospective multicenter study","volume":"35","author":"Kramer","year":"2007","journal-title":"Crit. Care Med."},{"issue":"8","key":"10.1016\/bs.acc.2022.03.002_bb0370","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s00134-009-1508-2","article-title":"Hypoxic hepatitis: underlying conditions and risk factors for mortality in critically ill patients","volume":"35","author":"Fuhrmann","year":"2009","journal-title":"Intensive Care Med."},{"issue":"14","key":"10.1016\/bs.acc.2022.03.002_bb0375","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.jacc.2019.01.053","article-title":"Acute noncardiac organ failure in acute myocardial infarction with cardiogenic shock","volume":"73","author":"Vallabhajosyula","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9","key":"10.1016\/bs.acc.2022.03.002_bb0380","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.4065\/81.9.1232","article-title":"Hypoxic liver injury","volume":"81","author":"Ebert","year":"2006","journal-title":"Mayo Clin. Proc."},{"issue":"3","key":"10.1016\/bs.acc.2022.03.002_bb0385","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/MOG.0000000000000355","article-title":"Current concepts in ischemic hepatitis","volume":"33","author":"Lightsey","year":"2017","journal-title":"Curr. Opin. Gastroenterol."},{"issue":"3","key":"10.1016\/bs.acc.2022.03.002_bb0390","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cld.573","article-title":"Congestive hepatopathy","volume":"8","author":"Hilscher","year":"2016","journal-title":"Clin. Liver Dis. (Hoboken)"},{"issue":"10","key":"10.1016\/bs.acc.2022.03.002_bb0395","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/eurheartj\/ehs332","article-title":"Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure","volume":"34","author":"Nikolaou","year":"2013","journal-title":"Eur. Heart J."},{"issue":"5","key":"10.1016\/bs.acc.2022.03.002_bb0400","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00392-016-1060-3","article-title":"Incidence, laboratory detection and prognostic relevance of hypoxic hepatitis in cardiogenic shock","volume":"106","author":"Jung","year":"2017","journal-title":"Clin. Res. Cardiol."},{"issue":"3","key":"10.1016\/bs.acc.2022.03.002_bb0405","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/01.SLA.0000055547.93484.87","article-title":"Hypoalbuminemia in acute illness: is there a rationale for intervention? A meta-analysis of cohort studies and controlled trials","volume":"237","author":"Vincent","year":"2003","journal-title":"Ann. Surg."},{"issue":"2","key":"10.1016\/bs.acc.2022.03.002_bb0410","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/MCA.0b013e32835c46fd","article-title":"The prognostic value of serum albumin levels on admission in patients with acute ST-segment elevation myocardial infarction undergoing a primary percutaneous coronary intervention","volume":"24","author":"Oduncu","year":"2013","journal-title":"Coron. Artery Dis."},{"issue":"5","key":"10.1016\/bs.acc.2022.03.002_bb0415","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217006","article-title":"Hypoalbuminemia is a frequent marker of increased mortality in cardiogenic shock","volume":"14","author":"Jantti","year":"2019","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/bs.acc.2022.03.002_bb0420","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/SHK.0000000000001195","article-title":"Intestinal fatty acid binding protein is associated with mortality in patients with acute heart failure or cardiogenic shock","volume":"51","author":"Kastl","year":"2019","journal-title":"Shock"},{"issue":"9677","key":"10.1016\/bs.acc.2022.03.002_bb0425","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/S0140-6736(09)60553-5","article-title":"Stress hyperglycaemia","volume":"373","author":"Dungan","year":"2009","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/bs.acc.2022.03.002_bb0430","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/dom.12078","article-title":"Dysglycaemia in the critically ill\u2014significance and management","volume":"15","author":"Deane","year":"2013","journal-title":"Diabetes Obes. Metab."},{"issue":"9206","key":"10.1016\/bs.acc.2022.03.002_bb0435","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0140-6736(99)08415-9","article-title":"Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview","volume":"355","author":"Capes","year":"2000","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/bs.acc.2022.03.002_bb0440","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.jacc.2012.11.054","article-title":"Association between elevated blood glucose and outcome in acute heart failure: results from an international observational cohort","volume":"61","author":"Mebazaa","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"issue":"8","key":"10.1016\/bs.acc.2022.03.002_bb0445","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1253\/circj.70.1064","article-title":"Prognostic value of blood glucose in patients with cardiogenic shock","volume":"70","author":"Tada","year":"2006","journal-title":"Circ. J."},{"issue":"6","key":"10.1016\/bs.acc.2022.03.002_bb0450","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.ahj.2007.07.028","volume":"154","author":"Vis","year":"2007","journal-title":"Am. Heart J."},{"issue":"5","key":"10.1016\/bs.acc.2022.03.002_bb0455","doi-asserted-by":"crossref","first-page":"R218","DOI":"10.1186\/cc13035","article-title":"Prognostic value of admission blood glucose level in patients with and without diabetes mellitus who sustain ST segment elevation myocardial infarction complicated by cardiogenic shock","volume":"17","author":"Yang","year":"2013","journal-title":"Crit. Care"},{"issue":"6","key":"10.1016\/bs.acc.2022.03.002_bb0460","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00392-018-1213-7","article-title":"Prognostic impact of baseline glucose levels in acute myocardial infarction complicated by cardiogenic shock-a substudy of the IABP-SHOCK II-trial [corrected]","volume":"107","author":"Abdin","year":"2018","journal-title":"Clin. Res. Cardiol."},{"issue":"6","key":"10.1016\/bs.acc.2022.03.002_bb0465","first-page":"626","article-title":"The association of diabetes and admission blood glucose with 30-day mortality in patients with acute myocardial infarction complicated by cardiogenic shock","volume":"9","author":"Thoegersen","year":"2020","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"issue":"2","key":"10.1016\/bs.acc.2022.03.002_bb0470","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41581-018-0087-2","article-title":"Renal and extrarenal effects of fibroblast growth factor 23","volume":"15","author":"Vervloet","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"issue":"1","key":"10.1016\/bs.acc.2022.03.002_bb0475","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.semnephrol.2018.10.005","article-title":"Fibroblast growth factor 23 and klotho in AKI","volume":"39","author":"Christov","year":"2019","journal-title":"Semin. Nephrol."},{"issue":"3","key":"10.1016\/bs.acc.2022.03.002_bb0480","first-page":"211","article-title":"FGF-23 is associated with increased disease severity and early mortality in cardiogenic shock","volume":"2","author":"Poss","year":"2013","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"issue":"6","key":"10.1016\/bs.acc.2022.03.002_bb0485","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1186\/s13054-014-0713-8","article-title":"Fibroblast growth factor 23 in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy of the Intraaortic balloon pump in cardiogenic shock II (IABP-SHOCK II) trial","volume":"18","author":"Fuernau","year":"2014","journal-title":"Crit. Care"},{"issue":"8","key":"10.1016\/bs.acc.2022.03.002_bb0490","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/ejhf.117","article-title":"Growth-differentiation factor 15 and osteoprotegerin in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy of the IABP-SHOCK II-trial","volume":"16","author":"Fuernau","year":"2014","journal-title":"Eur. J. Heart Fail."},{"issue":"5","key":"10.1016\/bs.acc.2022.03.002_bb0495","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1161\/CIRCULATIONAHA.106.613596","article-title":"Cardiogenic shock: current concepts and improving outcomes","volume":"117","author":"Reynolds","year":"2008","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/bs.acc.2022.03.002_bb0500","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1001\/archinte.165.14.1643","article-title":"Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock","volume":"165","author":"Kohsaka","year":"2005","journal-title":"Arch. Intern. Med."},{"issue":"2","key":"10.1016\/bs.acc.2022.03.002_bb0505","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/SHK.0000000000000756","article-title":"Infectious complications and immune\/inflammatory response in cardiogenic shock patients: a prospective observational study","volume":"47","author":"Parenica","year":"2016","journal-title":"Shock"},{"issue":"9","key":"10.1016\/bs.acc.2022.03.002_bb0510","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1097\/00003246-200209000-00007","article-title":"Multiple organ failure in patients with cardiogenic shock is associated with high plasma levels of interleukin-6","volume":"30","author":"Geppert","year":"2002","journal-title":"Crit. Care Med."},{"issue":"8","key":"10.1016\/bs.acc.2022.03.002_bb0515","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1097\/01.CCM.0000228919.33620.D9","article-title":"Plasma concentrations of interleukin-6, organ failure, vasopressor support, and successful coronary revascularization in predicting 30-day mortality of patients with cardiogenic shock complicating acute myocardial infarction","volume":"34","author":"Geppert","year":"2006","journal-title":"Crit. Care Med."},{"issue":"5","key":"10.1016\/bs.acc.2022.03.002_bb0520","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00392-011-0403-3","article-title":"Interleukin-6, -7, -8 and -10 predict outcome in acute myocardial infarction complicated by cardiogenic shock","volume":"101","author":"Prondzinsky","year":"2012","journal-title":"Clin. Res. Cardiol."},{"key":"10.1016\/bs.acc.2022.03.002_bb0525","doi-asserted-by":"crossref","first-page":"16045","DOI":"10.1038\/nrdp.2016.45","article-title":"Sepsis and septic shock","volume":"2","author":"Hotchkiss","year":"2016","journal-title":"Nat. Rev. Dis. Primers."},{"issue":"4","key":"10.1016\/bs.acc.2022.03.002_bb0530","doi-asserted-by":"crossref","first-page":"R152","DOI":"10.1186\/cc11467","article-title":"Interleukin-6 is the strongest predictor of 30-day mortality in patients with cardiogenic shock due to myocardial infarction","volume":"16","author":"Andrie","year":"2012","journal-title":"Crit. Care"},{"issue":"23","key":"10.1016\/bs.acc.2022.03.002_bb0535","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1056\/NEJM198806093182301","article-title":"Detection of circulating tumor necrosis factor after endotoxin administration","volume":"318","author":"Michie","year":"1988","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/bs.acc.2022.03.002_bb0540","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1378\/chest.118.2.503","article-title":"Proinflammatory cytokines","volume":"118","author":"Dinarello","year":"2000","journal-title":"Chest"},{"issue":"Suppl. 1","key":"10.1016\/bs.acc.2022.03.002_bb0545","first-page":"S57","article-title":"Physiology and genetics of procalcitonin","volume":"49","author":"Maruna","year":"2000","journal-title":"Physiol. Res."},{"issue":"4","key":"10.1016\/bs.acc.2022.03.002_bb0550","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/00313020701444564","article-title":"Procalcitonin for the clinical laboratory: a review","volume":"39","author":"Schneider","year":"2007","journal-title":"Pathology"},{"issue":"8","key":"10.1016\/bs.acc.2022.03.002_bb0555","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1007\/s00134-003-1827-7","article-title":"Usefulness of procalcitonin for diagnosing complicating sepsis in patients with cardiogenic shock","volume":"29","author":"Geppert","year":"2003","journal-title":"Intensive Care Med."},{"issue":"22","key":"10.1016\/bs.acc.2022.03.002_bb0560","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1093\/eurheartj\/ehs487","article-title":"Circulating angiopoietins and cardiovascular mortality in cardiogenic shock","volume":"34","author":"Link","year":"2013","journal-title":"Eur. Heart J."},{"issue":"11","key":"10.1016\/bs.acc.2022.03.002_bb0565","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/ejhf.342","article-title":"Angiopoietin-2 in acute myocardial infarction complicated by cardiogenic shock--a biomarker substudy of the IABP-SHOCK II-Trial","volume":"17","author":"Poss","year":"2015","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/bs.acc.2022.03.002_bb0570","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1755-8794-2-2","article-title":"Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases","volume":"2","author":"Kell","year":"2009","journal-title":"BMC Med. Genomics"},{"issue":"11","key":"10.1016\/bs.acc.2022.03.002_bb0575","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.2215\/CJN.02840314","article-title":"Plasma catalytic iron, AKI, and death among critically ill patients","volume":"9","author":"Leaf","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/bs.acc.2022.03.002_bb0580","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ijcard.2016.11.072","article-title":"Catalytic iron in acute myocardial infarction complicated by cardiogenic shock\u2014A biomarker substudy of the IABP-SHOCK II-trial","volume":"227","author":"Fuernau","year":"2017","journal-title":"Int. J. Cardiol."},{"issue":"15","key":"10.1016\/bs.acc.2022.03.002_bb0585","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1001\/jama.297.15.joc70035","article-title":"Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial","volume":"297","author":"Investigators","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/bs.acc.2022.03.002_bb0590","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.pharmthera.2018.01.001","article-title":"Inflammation following acute myocardial infarction: multiple players, dynamic roles, and novel therapeutic opportunities","volume":"186","author":"Ong","year":"2018","journal-title":"Pharmacol. Ther."},{"issue":"3","key":"10.1016\/bs.acc.2022.03.002_bb0595","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1161\/01.RES.0000207919.83894.9d","article-title":"GDF15, a cardioprotective TGF-beta superfamily protein","volume":"98","author":"Ago","year":"2006","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/bs.acc.2022.03.002_bb0600","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1373\/clinchem.2016.255174","article-title":"Growth differentiation factor 15 as a biomarker in cardiovascular disease","volume":"63","author":"Wollert","year":"2017","journal-title":"Clin. Chem."},{"issue":"2","key":"10.1016\/bs.acc.2022.03.002_bb0605","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1373\/clinchem.2006.076828","article-title":"Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay","volume":"53","author":"Kempf","year":"2007","journal-title":"Clin. Chem."},{"issue":"10035","key":"10.1016\/bs.acc.2022.03.002_bb0610","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/S0140-6736(16)00741-8","article-title":"The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study","volume":"387","author":"Hijazi","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/bs.acc.2022.03.002_bb0615","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/eurheartj\/ehx584","article-title":"A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score","volume":"39","author":"Hijazi","year":"2018","journal-title":"Eur. Heart J."},{"issue":"11","key":"10.1016\/bs.acc.2022.03.002_bb0620","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.cardfail.2019.07.003","article-title":"Levels of growth differentiation factor 15 and early mortality risk stratification in cardiogenic shock","volume":"25","author":"Hongisto","year":"2019","journal-title":"J. Card. Fail."},{"issue":"10","key":"10.1016\/bs.acc.2022.03.002_bb0625","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nrd2660","article-title":"The IL-33\/ST2 pathway: therapeutic target and novel biomarker","volume":"7","author":"Kakkar","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"issue":"17","key":"10.1016\/bs.acc.2022.03.002_bb0630","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/j.jacc.2019.08.1039","article-title":"Clinical and prognostic significance of sST2 in heart failure: JACC review topic of the week","volume":"74","author":"Aimo","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/bs.acc.2022.03.002_bb0635","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.immuni.2005.09.015","article-title":"IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines","volume":"23","author":"Schmitz","year":"2005","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/bs.acc.2022.03.002_bb0640","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.hfc.2017.08.005","article-title":"Soluble ST2 in heart failure","volume":"14","author":"McCarthy","year":"2018","journal-title":"Heart Fail. Clin."},{"issue":"18","key":"10.1016\/bs.acc.2022.03.002_bb0645","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.jacc.2008.07.042","article-title":"Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure","volume":"52","author":"Rehman","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/bs.acc.2022.03.002_bb0650","first-page":"205","article-title":"Soluble ST2 levels in patients with cardiogenic and septic shock are not predictors of mortality","volume":"17","author":"Parenica","year":"2012","journal-title":"Exp. Clin. Cardiol."},{"issue":"2","key":"10.1016\/bs.acc.2022.03.002_bb0655","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/SHK.0000000000000756","article-title":"Infectious complications and immune\/inflammatory response in cardiogenic shock patients: a prospective observational study","volume":"47","author":"Parenica","year":"2017","journal-title":"Shock"},{"issue":"2","key":"10.1016\/bs.acc.2022.03.002_bb0660","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/ejhf.1600","article-title":"Circulating dipeptidyl peptidase 3 and alteration in haemodynamics in cardiogenic shock: results from the OptimaCC trial","volume":"22","author":"Takagi","year":"2020","journal-title":"Eur. J. Heart Fail."},{"issue":"2","key":"10.1016\/bs.acc.2022.03.002_bb0665","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/ejhf.1601","article-title":"Circulating dipeptidyl peptidase 3 is a myocardial depressant factor: dipeptidyl peptidase 3 inhibition rapidly and sustainably improves haemodynamics","volume":"22","author":"Deniau","year":"2020","journal-title":"Eur. J. Heart Fail."},{"issue":"8","key":"10.1016\/bs.acc.2022.03.002_bb0670","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0238039","article-title":"Inhibition of circulating dipeptidyl-peptidase 3 restores cardiac function in a sepsis-induced model in rats: a proof of concept study","volume":"15","author":"Deniau","year":"2020","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/bs.acc.2022.03.002_bb0675","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.repc.2016.11.009","article-title":"Mid-regional pro-adrenomedullin and ST2 in heart failure: contributions to diagnosis and prognosis","volume":"36","author":"Lopes","year":"2017","journal-title":"Rev. Port. Cardiol."},{"issue":"5","key":"10.1016\/bs.acc.2022.03.002_bb0680","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcrc.2011.12.009","article-title":"Usefulness of cardiac biomarkers to predict cardiac recovery in patients on extracorporeal membrane oxygenation support for refractory cardiogenic shock","volume":"27","author":"Luyt","year":"2012","journal-title":"J. Crit. Care"},{"issue":"1","key":"10.1016\/bs.acc.2022.03.002_bb0685","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13613-016-0229-2","article-title":"Adrenomedullin: a marker of impaired hemodynamics, organ dysfunction, and poor prognosis in cardiogenic shock","volume":"7","author":"Tolppanen","year":"2017","journal-title":"Ann. Intensive Care"},{"issue":"1","key":"10.1016\/bs.acc.2022.03.002_bb0690","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.coi.2009.01.009","article-title":"TREM and TREM-like receptors in inflammation and disease","volume":"21","author":"Ford","year":"2009","journal-title":"Curr. Opin. Immunol."},{"issue":"1","key":"10.1016\/bs.acc.2022.03.002_bb0695","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ccc.2019.08.004","article-title":"Soluble triggering receptor expressed on myeloid Cells-1: diagnosis or prognosis?","volume":"36","author":"Lemarie","year":"2020","journal-title":"Crit. Care Clin."},{"key":"10.1016\/bs.acc.2022.03.002_bb0700","article-title":"Soluble triggering receptor expressed on myeloid cells-1 is a marker of organ injuries in cardiogenic shock: results from the CardShock Study","author":"Kimmoun","year":"2021","journal-title":"Clin. Res. Cardiol."},{"issue":"7","key":"10.1016\/bs.acc.2022.03.002_bb0705","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s00134-020-06109-z","article-title":"Nangibotide in patients with septic shock: a phase 2a randomized controlled clinical trial","volume":"46","author":"Francois","year":"2020","journal-title":"Intensive Care Med."},{"issue":"23","key":"10.1016\/bs.acc.2022.03.002_bb0710","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1016\/j.jacc.2016.09.945","article-title":"MicroRNAs in cardiovascular disease","volume":"68","author":"Barwari","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/bs.acc.2022.03.002_bb0715","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ehf2.12377","article-title":"Circulating levels of microRNA 423-5p are associated with 90 day mortality in cardiogenic shock","volume":"6","author":"Jantti","year":"2019","journal-title":"ESC Heart Fail."},{"issue":"2","key":"10.1016\/bs.acc.2022.03.002_bb0720","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3109\/1354750X.2013.870605","article-title":"Transcoronary gradient of plasma microRNA 423-5p in heart failure: evidence of altered myocardial expression","volume":"19","author":"Goldraich","year":"2014","journal-title":"Biomarkers"},{"issue":"21","key":"10.1016\/bs.acc.2022.03.002_bb0725","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21217925","article-title":"Association of miR-21-5p, miR-122-5p, and miR-320a-3p with 90-day mortality in cardiogenic shock","volume":"21","author":"Hanninen","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/bs.acc.2022.03.002_bb0730","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.recesp.2018.10.006","article-title":"Circulating MiRNA dynamics in ST-segment elevation myocardial infarction-driven cardiogenic shock","volume":"72","author":"Iborra-Egea","year":"2019","journal-title":"Rev. Esp. Cardiol. (Engl. Ed.)"},{"issue":"11","key":"10.1016\/bs.acc.2022.03.002_bb0735","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.1073\/pnas.0813371106","article-title":"Circulating microRNAs, potential biomarkers for drug-induced liver injury","volume":"106","author":"Wang","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/bs.acc.2022.03.002_bb0740","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1161\/CIRCGENETICS.110.957415","article-title":"Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease","volume":"3","author":"Corsten","year":"2010","journal-title":"Circ. Cardiovasc. Genet."},{"issue":"6","key":"10.1016\/bs.acc.2022.03.002_bb0745","first-page":"341","article-title":"MicroRNAs in pathophysiology of acute myocardial infarction and cardiogenic shock","volume":"119","author":"Goldbergova","year":"2018","journal-title":"Bratisl. Lek. Listy"},{"issue":"32","key":"10.1016\/bs.acc.2022.03.002_bb0750","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1093\/eurheartj\/ehz294","article-title":"Protein-based cardiogenic shock patient classifier","volume":"40","author":"Rueda","year":"2019","journal-title":"Eur. Heart J."}],"container-title":["Advances in Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242322000270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242322000270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T13:00:48Z","timestamp":1753707648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065242322000270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9780323988513"],"references-count":149,"URL":"https:\/\/doi.org\/10.1016\/bs.acc.2022.03.002","relation":{},"ISSN":["0065-2423"],"issn-type":[{"value":"0065-2423","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}